La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Scandinavian ChemoTech Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Stefan Frick

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	11.8yrs
Proprietà del CEO	6.3%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Stefan Frick (50 yo)

11.8yrs

Mandato

Mr. Stefan Mohan Frick founded Scandinavian ChemoTech AB in 2013 and has been its Chief Executive Officer since 2015. Mr. Frick has experience in life science marketing and sales from OnMeD, ArjoHuntleigh,...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stefan Frick	Founder	9.8yrs	Nessun dato	6.26% SEK 262.4k
Robin Sukhia	Independent Chairman	4.8yrs	Nessun dato	Nessun dato
Rolf Ehrnstrom	Independent Director	4.8yrs	Nessun dato	Nessun dato
Bengt Georg Engstrom	Independent Director	4.8yrs	Nessun dato	0.41% SEK 17.3k
Nicolas Pepin	Independent Director	1.8yrs	Nessun dato	Nessun dato

4.8yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 8V6 sono considerati esperti (durata media dell'incarico 4.6 anni).

Scandinavian ChemoTech Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Scandinavian Chemotech Thanks for the Cooperation with Its IR Consultant Who Leaves the Management Team

Robin Sukhia Elects as the New Chairman of the Board for Scandinavian ChemoTech AB (publ)

High number of new and inexperienced directors

Scandinavian Chemotech Appoints Dr. Mufti as Medical Director

Scandinavian ChemoTech AB (publ) Announces Management Changes

High number of new and inexperienced directors

Recent updates

Second quarter 2024 earnings released

New major risk - Shareholder dilution

Scandinavian Chemotech Announces Clinical Trial Progress

First quarter 2024 earnings released

New major risk - Revenue and earnings growth

Scandinavian Chemotech AB (Publ) Obtains Approval of the Third and Last Patent Application in India

Scandinavian ChemoTech AB (publ) Attains Progress by Obtaining Patent Protection for Two Essential Patents in India

Full year 2023 earnings released: kr1.52 loss per share (vs kr2.28 loss in FY 2022)

Scandinavian ChemoTech AB (publ) to Report Fiscal Year 2024 Results on Mar 04, 2025

Scandinavian ChemoTech AB (publ) to Report Q4, 2024 Results on Mar 04, 2025

Scandinavian Chemotech Thanks for the Cooperation with Its IR Consultant Who Leaves the Management Team

Third quarter 2023 earnings released

Scandinavian ChemoTech AB (publ) to Report Nine Months, 2023 Results on Oct 17, 2023

Second quarter 2023 earnings released

Robin Sukhia Elects as the New Chairman of the Board for Scandinavian ChemoTech AB (publ)

First quarter 2023 earnings released

Full year 2022 earnings released: kr2.36 loss per share (vs kr2.05 loss in FY 2021)

Scandinavian ChemoTech's Fully Owned Subsidiary Vetiqure Receives Very Promising Updates from the Veterinarians At the Royal Veterinary College

Scandinavian ChemoTech AB (publ) to Report Q1, 2023 Results on May 25, 2023

Third quarter 2022 earnings released

Scandinavian Chemotech Receives Updates For Cancer Patients Treated with IQwaveTM Tumour Specific Electroporation™ (Tse) At Ulis Hospital Ukraine

High number of new and inexperienced directors

Scandinavian Chemotech Appoints Dr. Mufti as Medical Director

Scandinavian ChemoTech AB (publ) to Report Q3, 2022 Results on Nov 22, 2022

Scandinavian ChemoTech AB (publ) Announces Management Changes

Second quarter 2022 earnings released

Scandinavian ChemoTech Announces TSE™ Therapy Has Been Initiated At Ulis Medical Centre in Ukraine

Scandinavian ChemoTech Receives Ethics Committee Approval for A Clinical Trial with the TSE Technology At All India Institute of Medical Sciences (AIIMS) in India

Scandinavian ChemoTech Receives New Patent on the Japanese Market

Scandinavian ChemoTech AB (publ) Receives Final Patent Approval in the EU for the Tumour Specific Control Unit in TSE™ Platform

High number of new and inexperienced directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Scandinavian ChemoTech AB (publ)'s TSE Technology Shows Great Initial Pre-Trial Results in India

Scandinavian Chemotech AB (Publ) Announces Demise of Göran Hellers, Co-Founder, Former Board Member

Scandinavian ChemoTech AB Receives Approval from the Us Patent Office

Third quarter 2021 earnings released

Scandinavian ChemoTech AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 18.000004 million.

Second quarter 2021 earnings released

Scandinavian ChemoTech Receives Approval from the European Patent Office

Scandinavian Chemotech AB Receives Approval for the CE Marking

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.93 loss per share (vs kr3.79 loss in FY 2019)

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media